14
DEC
2018
NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds
Comments : Off
BETHESDA, Md., December 14, 2018 – Northwest Biotherapeutics (OTCQB: NWBO) — (“NW Bio”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the package transaction involving the Company’s UK property, which the Company announced earlier this week, closed today in the UK. The closing included the transaction elements previously announced: The funding of approximately... Read More